Palvella Therapeutics: A Potential First-In-Class Therapy In A Rare Dermatology Market [Seeking Alpha]
Palvella Therapeutics, Inc. (PVLA)
Company Research
Source: Seeking Alpha
QTORIN's clinical profile demonstrates high efficacy and a benign safety profile, addressing a major unmet need in mLM and offering first-mover advantage in a niche orphan market. PVLA's mLM program alone could justify a multibillion-dollar valuation, with cVM label expansion potentially doubling revenue opportunity; current cash runway extends well beyond regulatory milestones. Key risks include regulatory uncertainty, payer leverage due to generics, and commercialization challenges typical for rare-disease biopharma. Tom Werner/DigitalVision via Getty Images Investment Thesis Palvella Therapeutics ( PVLA ) is developing medicine for a rare vascular skin disorder called microcystic lymphatic malformations (mLM), and secondary indications including cutaneous venous malformations (cVM). The topical formulation is called QTORIN rapamycin. While rapamycin is a generic molecule it doesn't have
Show less
Read more
Impact Snapshot
Event Time:
PVLA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PVLA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PVLA alerts
High impacting Palvella Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
PVLA
News
- Palvella Therapeutics (PVLA) had its "buy" rating reaffirmed by Chardan Capital. They now have a $210.00 price target on the stock.MarketBeat
- Palvella Therapeutics Announces Issuance of European Patent Covering Anhydrous Compositions of Rapamycin [Yahoo! Finance]Yahoo! Finance
- Palvella Therapeutics Announces Issuance of European Patent Covering Anhydrous Compositions of RapamycinGlobeNewswire
- Palvella Therapeutics Launches "BEYOND mLM" Disease Awareness Campaign for Microcystic Lymphatic Malformations in Collaboration with Leading Lymphatic, Vascular, and Dermatology Nonprofit Organizations [Yahoo! Finance]Yahoo! Finance
- Palvella Therapeutics Launches "BEYOND mLM" Disease Awareness Campaign for Microcystic Lymphatic Malformations in Collaboration with Leading Lymphatic, Vascular, and Dermatology Nonprofit OrganizationsGlobeNewswire
PVLA
Earnings
- 11/11/25 - Miss
PVLA
Sec Filings
- 3/2/26 - Form 4
- 3/2/26 - Form 4
- 2/26/26 - Form 8-K
- PVLA's page on the SEC website